Viewing Study NCT03497767


Ignite Creation Date: 2025-12-25 @ 12:44 AM
Ignite Modification Date: 2025-12-25 @ 10:56 PM
Study NCT ID: NCT03497767
Status: COMPLETED
Last Update Posted: 2024-05-31
First Post: 2018-02-26
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases
Sponsor: Trans Tasman Radiation Oncology Group
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module